46 related articles for article (PubMed ID: 10370375)
1. Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cells.
Shimizu M; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
Cancer Immunol Immunother; 1998 Nov; 47(3):143-8. PubMed ID: 9829839
[TBL] [Abstract][Full Text] [Related]
2. Fas
Bohat R; Liang X; Chen Y; Xu C; Zheng N; Guerrero A; Hou J; Jaffery R; Egan NA; Li Y; Tang Y; Unsal E; Robles A; Chen S; Major AM; Elldakli H; Chung SH; Liang H; Hicks MJ; Du Y; Lin JS; Chen X; Mohan C; Peng W
Clin Immunol; 2024 Jan; 258():109874. PubMed ID: 38113962
[TBL] [Abstract][Full Text] [Related]
3. Protection from autoimmune diabetes and T-cell lymphoproliferation induced by FasL mutation are differentially regulated and can be uncoupled pharmacologically.
Mohamood AS; Guler ML; Xiao Z; Zheng D; Hess A; Wang Y; Yagita H; Schneck JP; Hamad AR
Am J Pathol; 2007 Jul; 171(1):97-106. PubMed ID: 17591957
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of suboptimal CD8 cytotoxic T cell effector function in vivo using antigen-specific CD80 defective T cells.
Puliaeva I; Soloviova K; Puliaiev M; Lang T; Puliaev R; Via CS
J Immunol; 2011 Jan; 186(1):291-304. PubMed ID: 21115734
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of Fas and the costimulatory molecules B7-1 and B7-2 on peripheral lymphocytes in autoimmune B6/gld mice.
Weintraub JP; Eisenberg RA; Cohen PL
J Immunol; 1997 Oct; 159(8):4117-26. PubMed ID: 9379003
[TBL] [Abstract][Full Text] [Related]
6. T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.
Zhou T; Weaver C; Linsley PS; Mountz JD
Eur J Immunol; 1994 May; 24(5):1019-25. PubMed ID: 7514125
[TBL] [Abstract][Full Text] [Related]
7. Blockade of CD28/CTLA4-B7 pathway prevented autoantibody-related diseases but not lung disease in MRL/lpr mice.
Takiguchi M; Murakami M; Nakagawa I; Yamada A; Chikuma S; Kawaguchi Y; Hashimoto A; Uede T
Lab Invest; 1999 Mar; 79(3):317-26. PubMed ID: 10092068
[TBL] [Abstract][Full Text] [Related]
8. Immunological and pathological consequences of mutations in both Fas and Fas ligand.
Weintraub JP; Godfrey V; Wolthusen PA; Cheek RL; Eisenberg RA; Cohen PL
Cell Immunol; 1998 May; 186(1):8-17. PubMed ID: 9637760
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis abnormalities of splenic lymphocytes in autoimmune lpr and gld mice.
Reap EA; Leslie D; Abrahams M; Eisenberg RA; Cohen PL
J Immunol; 1995 Jan; 154(2):936-43. PubMed ID: 7529292
[TBL] [Abstract][Full Text] [Related]
10. Ectopic expression of B7-1 (CD80) on T lymphocytes in autoimmune lpr and gld mice.
Weintraub JP; Cohen PL
Clin Immunol; 1999 Jun; 91(3):302-9. PubMed ID: 10370375
[TBL] [Abstract][Full Text] [Related]
11. Cellular interactions in the lpr and gld models of systemic autoimmunity.
Sobel ES
Adv Dent Res; 1996 Apr; 10(1):76-80. PubMed ID: 8934931
[TBL] [Abstract][Full Text] [Related]
12. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.
Carreno BM; Collins M
Annu Rev Immunol; 2002; 20():29-53. PubMed ID: 11861596
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
